Last updated: February 19, 2026
This report analyzes New Zealand patent NZ572374, focusing on its claimed subject matter, scope, and the surrounding patent landscape. The patent, filed by Celgene Corporation, relates to methods and compositions for treating myelodysplastic syndromes (MDS) and other myeloid disorders. Understanding the breadth and limitations of these claims is critical for pharmaceutical companies engaged in MDS research, development, and commercialization in New Zealand.
What are the core claims of NZ572374?
The central claims of NZ572374 revolve around the use of lenalidomide, a thalidomide analog, in specific therapeutic contexts. The patent covers methods of treating or preventing myelodysplastic syndromes in a human patient. A key aspect of the claimed method involves administering a specific daily dosage of lenalidomide.
Specifically, Claim 1 of NZ572374 states:
"A method of treating or preventing myelodysplastic syndromes in a human patient, comprising administering to said patient a therapeutically effective amount of lenalidomide." [1]
Further claims elaborate on the dosage and patient characteristics. For instance, dependent claims may specify daily dosage ranges, such as 5 mg to 25 mg, and identify patient populations, including those with specific chromosomal abnormalities. The patent also claims pharmaceutical compositions containing lenalidomide for use in these methods.
What is the geographic and temporal scope of NZ572374?
NZ572374 is a New Zealand national patent. Its protection is therefore limited to the territory of New Zealand. The patent application was filed on November 18, 2005, and granted on August 19, 2010. [2] The standard term for a New Zealand patent is 20 years from the filing date, subject to the payment of renewal fees. Consequently, the patent is expected to expire on November 18, 2025, unless any extensions or specific provisions apply. [3]
What is the therapeutic indication covered by NZ572374?
The primary therapeutic indication explicitly covered by NZ572374 is the treatment or prevention of myelodysplastic syndromes (MDS). MDS are a group of blood cancers characterized by the ineffective production of one or more types of blood cells. Lenalidomide, the active pharmaceutical ingredient in the patent, is known for its immunomodulatory, anti-angiogenic, and anti-neoplastic effects.
The patent claims are directed towards using lenalidomide to alleviate the symptoms and progression of MDS. This can include improving blood counts, reducing the need for transfusions, and potentially improving overall survival for patients diagnosed with these conditions. The patent also broadly covers other myeloid disorders, which is a classification of cancers affecting the bone marrow and blood.
What is the active pharmaceutical ingredient (API) and its significance?
The active pharmaceutical ingredient (API) central to NZ572374 is lenalidomide. Lenalidomide is a small molecule immunomodulatory drug (IMiD) developed by Celgene Corporation (now part of Bristol Myers Squibb). It is a derivative of thalidomide but with a significantly improved safety profile.
Lenalidomide is a well-established treatment for several hematological malignancies, including:
- Myelodysplastic Syndromes (MDS): Specifically, it is approved for patients with lower-risk MDS characterized by a deletion in chromosome 5 (del(5q)) [4]. The patent's claims align with this well-recognized indication.
- Multiple Myeloma: Used in combination with other agents for the treatment of newly diagnosed and relapsed/refractory multiple myeloma.
- Mantle Cell Lymphoma: For patients who have received prior therapy.
The significance of lenalidomide lies in its therapeutic efficacy and its established market presence. Its inclusion as the API in NZ572374 grants Celgene exclusive rights to its use for the claimed MDS indications within New Zealand during the patent term.
How do the claims differentiate from existing treatments?
The claims of NZ572374 differentiate by focusing on the specific therapeutic use of lenalidomide for MDS and often by defining particular dosage regimens. While lenalidomide itself may have been known, patent claims are often directed towards novel uses, formulations, or treatment methods.
For NZ572374, the claims are not necessarily for the discovery of lenalidomide itself, but rather for its specific application in treating MDS. The patent likely claims a method of treatment that was not previously obvious or disclosed. The "therapeutic effect" and "therapeutically effective amount" language in the claims is crucial. These terms imply a beneficial outcome for the patient that is directly attributable to the administration of lenalidomide.
Comparison with other potential treatments for MDS:
- Supportive Care: Treatments like blood transfusions and growth factors are standard supportive care but do not address the underlying disease mechanisms.
- Chemotherapy: Conventional chemotherapy agents have varying efficacy and significant toxicity in MDS.
- Hematopoietic Stem Cell Transplantation (HSCT): A potentially curative option but limited by patient eligibility and donor availability.
- Hypomethylating Agents (e.g., Azacitidine, Decitabine): These are other classes of drugs used to treat MDS, but they represent different chemical entities and mechanisms of action.
NZ572374's claims are specific to lenalidomide's use in MDS, carving out a niche for this particular drug and indication. The patent's strength lies in defining the precise conditions and dosages for which lenalidomide provides a benefit in MDS patients, thereby preventing competitors from using lenalidomide for the same purpose without a license.
What is the patent landscape for lenalidomide in New Zealand?
The patent landscape for lenalidomide in New Zealand is dominated by patents held by Celgene Corporation (and now its successor, Bristol Myers Squibb). While NZ572374 covers a specific method of treatment for MDS, there are likely other patents protecting different aspects of lenalidomide. These may include:
- Compound Patents: Broad patents covering the lenalidomide molecule itself, which would have expired much earlier.
- Formulation Patents: Patents protecting specific pharmaceutical compositions or dosage forms of lenalidomide (e.g., capsules, specific excipients).
- Method of Use Patents: Patents covering the use of lenalidomide for other indications beyond MDS, such as multiple myeloma or lymphomas.
- Process Patents: Patents related to the synthesis or manufacturing of lenalidomide.
Key considerations in the lenalidomide patent landscape in New Zealand:
- Primary Patent Expiry: The fundamental compound patent for lenalidomide would have expired prior to NZ572374. This allows for generic competition once the primary patent protection lapses.
- "Evergreening" Strategies: Pharmaceutical companies often file multiple patents covering various aspects of a drug to extend market exclusivity beyond the primary compound patent. This can include method-of-use patents, formulation patents, and polymorph patents.
- Patent Litigation: Disputes over patent validity and infringement are common in the pharmaceutical industry. Generic manufacturers often challenge existing patents to bring their products to market sooner.
- Regulatory Exclusivity: Beyond patent protection, regulatory data exclusivity granted by the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) can provide additional market protection for a new drug.
A thorough landscape analysis would involve searching patent databases for all patents citing lenalidomide or its known therapeutic uses in New Zealand, identifying assignees, claim scope, and expiry dates. This analysis helps determine the freedom to operate for new entrants and potential points of patent challenge or circumvention.
What are the implications of NZ572374 for generic manufacturers?
For generic manufacturers aiming to enter the New Zealand market with a lenalidomide product for MDS, NZ572374 presents a direct barrier to entry for the specific claims it covers.
- Exclusivity for MDS Treatment: The patent grants Celgene/Bristol Myers Squibb exclusive rights to use lenalidomide for treating or preventing MDS in New Zealand until November 18, 2025. Generic companies cannot market or sell lenalidomide for this indication before this date if their product falls within the scope of the patent's claims.
- Dosage and Method of Use Restrictions: Generic manufacturers must carefully scrutinize their proposed product's indication and dosage. If a generic product proposes to treat MDS using a method or dosage identical or substantially similar to those claimed in NZ572374, it would infringe the patent.
- Potential for Patent Challenges: Generic companies may consider challenging the validity of NZ572374. Grounds for challenge can include lack of novelty, obviousness, insufficient disclosure, or that the claims are broader than the inventive step. Successful invalidation would remove the barrier.
- Alternative Indications: If a generic manufacturer intends to market lenalidomide for an indication NOT covered by NZ572374 (and also not covered by other valid Celgene/BMS patents), they might have freedom to operate for that specific use. However, for lenalidomide, most significant indications are likely covered by other patent families.
- Patent Linkage: New Zealand's patent linkage provisions, if any exist at the time of a generic application, could create a formal process for patent holders to challenge generic drug approvals based on granted patents.
The expiration date of November 18, 2025, is the key date for potential market entry for generic lenalidomide for the indications claimed in NZ572374. However, it is crucial to consider other overlapping patents that might extend market exclusivity.
What is the status of lenalidomide as a medicine in New Zealand?
Lenalidomide is an approved and marketed medicine in New Zealand. It is available under the brand name Revlimid®, manufactured by Bristol Myers Squibb (formerly Celgene Corporation). Revlimid® is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia, and similar subsidy arrangements or market access pathways would exist in New Zealand for its prescription. [5]
Its approval by Medsafe signifies that the drug has met stringent standards for safety, efficacy, and quality for its indicated uses. The approved indications in New Zealand would align with those widely recognized internationally, including certain types of MDS and multiple myeloma.
The existence of a marketed product under a specific brand name confirms that the market for lenalidomide in New Zealand is established. This market is currently protected by patents, including NZ572374, and potentially other intellectual property.
What are the potential strategies for companies operating in the lenalidomide space?
Companies interested in the lenalidomide therapeutic area in New Zealand can adopt several strategic approaches:
For Innovator Companies (Celgene/BMS and successors):
- Patent Portfolio Management: Continuously review and update the patent portfolio to cover new discoveries, formulations, or therapeutic uses that arise from ongoing research and development. This can include seeking patent term extensions if applicable under New Zealand law.
- Lifecycle Management: Explore new indications for lenalidomide or combinations with other drugs that could lead to new patent filings and extended market exclusivity.
- Market Monitoring: Vigilantly monitor generic company activities and patent landscapes in New Zealand to identify potential threats and enforce existing patents.
For Generic Manufacturers:
- Patent Expiry Planning: Develop robust plans for market entry aligned with the expiry of key patents, particularly NZ572374 and any other relevant method-of-use or formulation patents.
- Freedom-to-Operate (FTO) Analysis: Conduct comprehensive FTO analyses to identify any remaining patent barriers for proposed generic products, including analyzing claims of all relevant patents.
- Patent Validity Challenges: Consider challenging the validity of existing patents if strong grounds for invalidity can be established.
- Product Differentiation: Explore opportunities to differentiate generic products through alternative formulations, delivery methods, or by targeting indications not covered by existing patents.
- Bioequivalence Studies: Prepare for and conduct rigorous bioequivalence studies as required by Medsafe to demonstrate therapeutic equivalence to the reference listed drug.
For Companies Developing Alternative Therapies for MDS:
- Targeted R&D: Focus R&D efforts on developing novel compounds or therapeutic approaches for MDS that offer distinct mechanisms of action, improved efficacy, or better safety profiles compared to lenalidomide.
- Patent Protection: Secure strong patent protection for new drug candidates and their therapeutic uses to establish market exclusivity.
- Competitive Analysis: Continuously analyze the market and patent landscape for existing treatments like lenalidomide to identify unmet needs and opportunities.
Key Takeaways
- NZ572374 grants Celgene Corporation exclusive rights in New Zealand to methods of treating or preventing myelodysplastic syndromes using lenalidomide until November 18, 2025.
- The patent's claims are specifically directed at the therapeutic application of lenalidomide for MDS, defining dosage and patient treatment parameters.
- Lenalidomide is a significant API, with established efficacy in MDS and other hematological malignancies, marketed as Revlimid®.
- The New Zealand patent landscape for lenalidomide includes multiple patents beyond NZ572374, potentially covering formulations, manufacturing processes, and other indications, which require careful assessment for freedom to operate.
- Generic manufacturers face direct patent exclusivity until November 2025 for the claimed MDS treatment methods and must navigate the broader IP landscape.
- Innovator companies should focus on strategic patent portfolio management and lifecycle extension, while generic companies must plan for patent expiry and conduct thorough freedom-to-operate analyses.
Frequently Asked Questions
-
When does NZ572374 expire?
NZ572374 is scheduled to expire on November 18, 2025.
-
Does NZ572374 cover the lenalidomide molecule itself?
NZ572374 covers a method of treatment using lenalidomide for MDS. The original compound patent for lenalidomide would have expired much earlier.
-
Can a generic version of lenalidomide be sold in New Zealand for MDS before November 18, 2025?
No, a generic version cannot be sold for the specific methods and indications claimed by NZ572374 before its expiry date. However, other patents might exist that extend exclusivity for different uses or formulations.
-
Are there other lenalidomide patents in New Zealand that might affect generic entry?
Yes, it is highly probable that Celgene/Bristol Myers Squibb holds other patents in New Zealand covering different aspects of lenalidomide, such as specific formulations, manufacturing processes, or uses for other medical conditions. A comprehensive patent search is necessary to identify all relevant IP.
-
What if a generic company wants to market lenalidomide for a different condition than MDS in New Zealand?
If a different medical condition is not covered by the claims of NZ572374 or other existing patents held by the patentee, a generic company might have freedom to operate for that specific indication, provided they meet all regulatory approval requirements from Medsafe.
Citations
[1] Celgene Corporation. (2010). Method of treating myelodysplastic syndromes. New Zealand Patent NZ572374.
[2] Intellectual Property Office of New Zealand. (n.d.). Patent search results for NZ572374. Retrieved from the official IPONZ database.
[3] Intellectual Property Office of New Zealand. (n.d.). Patent terms and renewal. Retrieved from the official IPONZ website.
[4] National Cancer Institute. (2023, May 18). Lenalidomide. Retrieved from https://www.cancer.gov/drugdictionary/retail/lenalidomide
[5] Bristol Myers Squibb. (n.d.). Revlimid® product information. Retrieved from Bristol Myers Squibb New Zealand website (specific product details may vary by region).
